Enliven Therapeutics (ELVN) EPS (Diluted) Growth (1y) (2022 - 2026)
Enliven Therapeutics (ELVN) EPS (Diluted) Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 36.94% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17,091.12% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 61.58% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -7.16% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 96.09% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | 29.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.95% |
| Dec 31, 2025 | -6.08% |
| Sep 30, 2025 | 26.69% |
| Jun 30, 2025 | -8.10% |
| Mar 31, 2025 | -2.38% |
| Dec 31, 2024 | 65.18% |
| Sep 30, 2024 | 6.44% |
| Jun 30, 2024 | -4.86% |
| Mar 31, 2024 | 30.16% |
| Dec 31, 2023 | 63.51% |
| Sep 30, 2023 | 64.71% |
| Jun 30, 2023 | 65.66% |
| Mar 31, 2023 | 71.29% |
| Dec 31, 2022 | -69.64% |
| Sep 30, 2022 | 45.76% |
| Jun 30, 2022 | 62.50% |